Page last updated: 2024-12-07
propizepine
Description
Propizepine is a tricyclic antidepressant (TCA) with anticholinergic and antihistaminic properties. It was synthesized in the 1960s and was initially marketed for the treatment of depression. However, its use was limited due to its side effects, including drowsiness, dry mouth, blurred vision, and constipation. Propizepine has also been investigated for its potential use in treating anxiety disorders, obsessive-compulsive disorder, and epilepsy. It is thought to exert its antidepressant effects by blocking the reuptake of serotonin and norepinephrine in the brain. Propizepine is currently not available in the United States but is still available in some European countries. Research on propizepine is limited, and further investigation is needed to fully understand its therapeutic potential and safety profile.'
propizepine: RN given refers to parent cpd; synonym UP 106 refers to HCl; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
Synonyms (27)
Synonym |
propizepine |
CHEBI:135250 |
6-[2-(dimethylamino)propyl]-11h-pyrido[3,2-c][1,5]benzodiazepin-5-one |
09b57945v9 , |
propizepine [inn:dcf] |
einecs 233-705-9 |
propizepinum |
10321-12-7 |
unii-09b57945v9 |
up 106 |
propizepina |
6,11-dihydro-6-(2-(dimethylamino)-2-methylethyl)-5h-pyrido(2,3-b)(1,5)benzodiazepin-5-one |
propizepinum [inn-latin] |
propizepina [inn-spanish] |
vagran 50 |
CHEMBL2104749 |
5h-pyrido(2,3-b)(1,5)benzodiazepin-5-one, 6-(2-(dimethylamino)propyl)-6,11-dihydro- |
propizepine [mi] |
(+/-)-propiezepine |
propiezepine, (+/-)- |
propizepine [inn] |
SCHEMBL49421 |
propizepin |
YFLBETLXDPBWTD-UHFFFAOYSA-N |
Q7250340 |
DTXSID20864247 |
6-[2-(dimethylamino)propyl]-6,11-dihydro-5h-pyrido[2,3-b][1,5]benzodiazepin-5-one |
Drug Classes (1)
Class | Description |
organonitrogen heterocyclic compound | Any organonitrogen compound containing a cyclic component with nitrogen and at least one other element as ring member atoms. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (3)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.43
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.43 (24.57) | Research Supply Index | 1.95 (2.92) | Research Growth Index | 4.37 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (16.67%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (83.33%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |